and brief joining earnings year operator. you a with start you, for Thank I'll quarter first fiscal call. thank everyone, of first XXXX performance. revenue our review our Hello of today quarter remarks for us my
quarter In million, year-over-year XXXX, $XX.X total of on revenue growth X% representing fiscal the basis. of we achieved first a
Importantly, earnings total in on quarter, shared which revenue our the our performance we for our expectations first November. call exceeded
IVD revenue total higher than or exclusively year-over-year, Medical by our revenue, was Our anticipated which than a revenue. growth In X% Diagnostics our Vitro driven offsetting Device more XX% increased decrease in
strong sales our contribution performance products. Device our important Pounce was our business, primarily year-over-year of Medical Sublime our by reagents growth and Within of products, and sales coating sales from including device driven
first our we license revenue In with were pleased higher quarter. saw and royalty summary, also revenue. We results in the largely fee
the during drug-coated XXXX further update revenue including key on financial SurVeil™ and our operational performance, our But our fiscal of weeks, during me our quarter other with in detail updated remarks. balloon. guidance fiscal first beginning Tim prepared let some recent an first, will developments discuss talk through in his and
press PMA we call, to earnings agency response November our on and application, comments finalized shared our As SurVeil XX SurVeil. application receipt letter, we indicated team on application On our release complete the related FDAs response letter the a PMA regulatory submitted the January the our to that clinical our in for XX. to and FDA announcing is October a the issued our In on our its we FDA of approvable from not current form. the PMA the
of their additional understandably necessary, have are dedication collaboratively receive this in interactions given clarification, the work provide We agency as been on letter, with our to recent month. requests and our and the data testing who with address numerous to disappointed FDA hard focused well working as team and the as
that a denial of is permanent It approvable application be our information decision. letter understand PMA in approval’ important must ‘not to The is the form. guidance specific place to terms added order in a an to provided in agency that not it
routine raised agency questions and biocompatibility, to our additional non-clinical additional We questions questions. the with to And and as testing labeling to FDAs addressed. it respect and generally shared The to the agency the incorporating and instructions patient for two information revised the general requested labeling, of language respect devices labeling agency use, With categories, revisions language data revisions. easily be the these that some the address requested viewed related can biocompatibility. believe within to related requested to and was these labeling
while and Conference substantially sustained using represented dose ISET SurVeil to both on clinical is SurVeil at a let With and and efficacy the say leading January equivalent a the outcomes conference known device, current to SurVeil we which effective. that clinical VIVA for TRANSCEND patients that outcomes. are at believe which reflected the cytotoxic XX, the First, lower on the safety market most that data safe me demonstrated month our of XX X, continue in November drug. from outcomes trial, durability recently are of These
clinical outcomes primary months comparable and more impact efficacy SurVeil endpoints, XX% XX safety demonstrated and DCB and the cohorts, data these between despite Specifically, the the sustained the DCB both IN.PACT paclitaxel. having in Admiral through
FDA As engineering. further With Moreover, and there analysis to are respect it not no from TRANSCEND biocompatibility that specifically, concern to relates the I our not questions address. studies, animal into any cited including did were to human also did clinical and the requests that received want clinical letter the that quest letter we require submitted, non-human data clinical with letter with large testing the stress said, to do human additional data our request the trial. data the
In we with with and our since focused external preparing evaluating in clinical the the to the engage conjunction our its been have regulatory content teams, received formally advisers and days on letter, DFA.
the representatives an our has preparing Specifically, review through with now team is and had call FDAs the process. FDA Q-submission to informal obtain team feedback Agency from the request a
letter. clarification to of see requirements for to under and additional outlined is items The the goal obtain request in and this FDA the the feedback analysis testing specific address
the Assuming this May. our formal anticipate receiving and in normal FDAs feedback process timelines, we via proposed approach
the FDA following letter, them we informed tandem, provided and of our a of with partner copy Abbott, receipt the the In commercial communication.
with as I proceed productive continuously that outlined. remain Abbott with FDA the just steps we the interactions Our next
agency details. decision. process, these amended is sharing external this perusing determine for advisors clarity from our Our we'll forward the is and during receive to and will upon this to from the Based appropriate received additional application path feedback the what forward, required to an the overarching additional on agency team goal steps obtain in approval look
additional While path community the important continue navigate to we it investment considerations as we and believe process. the to for clarity appreciate some is forwarded, we important to the of regulatory evaluate the obtain work
with be that the us questions while agency, not level able or optimistic, may First, we evidence could request. proceed engagement the for be we'll learn the we're to address through it practical our to FDAs of
would strategy we to to reevaluate need commercial and regulatory this occur, the if While product. our were unlikely, for
our at we our shared before if SurVeil agreement million past, payment final least $XX have and we second, with obtain distribution the development are The a for approval to XX PMA under we of the entitled December this year, milestone of chooses milestone we to as payment million in commercial of PMA XX, that agreement. Abbott product receipt commercialize terminate the to Abbot. After and does following the remain right entitled partner, provided exercise the this December approval, to $XX not their
DCB, team Ultimately, the despite to this productive. our path of unfortunate development focused commercialization in our remains and SurVeil
We'll product engage with with agency have in the We the our commercial outlined, as partner that path with additional we providing the to as strategy innovative additional community on will as and our bringing the of as obtain steps investment patients and to efficiently I continue from look to regulatory goal and possible. process our next navigate forward. Abbott information the forward determine FDA the details physicians to this we
other XXXX. progress thrombectomy Now, let to for on and second our Sublime Pounce update our with with strategic me of objectives advance fiscal our related platform. strategic commercialization arterial radial provide our objective, to Beginning you an the initial
across the account XXXX, and territory managers our orders established direct force base expanded first building quarter repeat drive focus During recently continued on sales of customer to our our base. of XX
in and Endovascular medicine. Sublime supplements publications raised viewed market one is team the and published Endovascular of as of Our platforms, today, brand national successfully in product two Pounce with which our most has awareness development dedicated recognized
of revolutions for radial and XXXX The access in gaining products published risks radial of our compelling by line peripheral the was foodsupplement Sublime November a in space outlines case spearheaded the is to Sublime momentum.
approach impact With from access a the operators be will positive of hospitals and for benefits labs, important patients. of office on radial a Endovascular based owners and having procedures shift moving centers to ambulatory strategically while
intensive of The clot understand mission capital and of solution committed [inaudible] versus efficient traditional the grab-and-go increased exemplifies risk to need to the importance want the about for and recommend of why more our arterial read these I Endovascular Pounce today, December and has these of a a reinforces we significantly procedures. exist the if device XXXX, bringing incredible surgical more you results. technologies in supplement market. you was to offers to our era, simple, that devices for thrombectomy that In table on highly each published post-COVID and remain which the complex the success
Our engaging XXX or am XXX get pleased Value quarter of and strong progress with hospitals to through clinics I for our products ended report end that approved over team new total their them potential with working Pounce and Committee. with to Analysis fiscal over customers the to in has customers compared XXXX. at made we Sublime, the
at has the And committees XXXX. the pipeline a healthy end prospective first of end considering lastly, the value by expand compared more fiscal analysis At pace. than of quarter, increased our products XX% of that to number continued are the to of our customers
which base programs, an are and impact of a of the end. We new commercialization remain we to continue interest. drive approximately months at awareness and sales education the Ultimately, customer for our in but small, market to brand tenure nine growing months quarter customer force initial with see average beginning
ongoing our to remain continue a building and of find performance nine Looking I'm for accelerate the XXXX of commercial areas. to and ahead, clinical focused foundation these we year of our we progress recent first about ways growth. through progress our next continue in strong as months through on fiscal commercialization the excited will to offering full growth future lead
update our on Pounce venous device. an thrombectomy Lastly,
and wide will while evaluations experience conduct viability. and feedback the evaluations patients evaluate potential to a from obtained cases physicians. real have we benefit enhancements design commercial conditions market We inform recently that variety The begun limited world help to its renewed clinical these of through venous feedback optimizing future and physicians that numerous across
objective, during IVD flow our performance to Diagnostic Medical the offerings performance from coatings first quarter. businesses. drive speaking, our Medical we first to revenue core XX%, year-over-year and strategic of our decreased respect pleased from cash in overall revenue Device coatings Device with Revenue were offerings quarter. grew our our from business With Broadly businesses third the while X% and growth
a IVD direct of initiatives, our operating the force. our the driven primarily in of businesses in Now by support revenue was to flow the the customer year-over-year generated completion program. development Together, sales to related cash increase growth these including expenses significant decrease expansion
operational this discuss now a have spending update the as we I'd turn with like implemented. as reduction recently to backdrop, So an to plan
in our to January to SurVeil our Abbott that milestone options evaluate strategic PMA As press FDAs second action to capital as fiscal prioritize and on related order our in us preserve we growth response anticipated. the payment the as receive take which application, This key release not we quarter investment will we prompted in XX, our indicated means in initiatives.
expenditures result, to our is charges. restructuring R&D. the we remainder and Approximately recently planned by $XX plan, reduce use of spending reduction a for implemented million from of capital prior million to XX% XX% spending have of to SG&A, approximately the a $XX XX% cash XXXX, designed reduction As fiscal from from the
Importantly, this to plan carefully impact is created after to not serve ability We expect customers, nor do to our our it our valuation. respond and implemented to ability FDA.
additional plan saving components; includes workforce spending cash a two reduction The restructuring primary measures. and
Let several clinical, areas me R&D sales These headcount. in involves workforce to are so both continue our take operations manufacturing a these in the and our our reduction and execute more that minute and operations, of teams business, in strategies in components force, detail. employee some streamline fiscal to a including The more refocus and efficiently to ’XX. we sales XX% growth workforce can direct our restructuring reductions intended of cover
our SurVeil, have core regulatory and support our manufacturer number support a clinical On of front, the of SurVeil retaining manufacturer a manufacturing, positions we technical, and personnel. that key balloon drug-coated team including that reduced while operations
front, the commercial the discuss to investment optimize reduced in radial a priorities size development headcount in operations. and R&D thrombectomy have product we access finally, aligned to minute. our products and R&D organization, our which standpoint, our support And we've clinical sales a supporting Pounce our current I'll of our On from Sublime
today's to development on territory the of fiscal of remainder a for savings direct sales driving and opportunities. our committed XXXX progress, and focused measures and to remains our call, that of and platforms. additional growth mentioned, consists of CapEx, reduction in of the XX The planned our including force hiring Our our now product managers plan prioritize a cash in these I investments commercialization refocusing near term primarily product as reduction
standpoint, product Sublime we'll product In Pounce terms of efforts the platforms. development our our on areas Pounce and a priorities product arterial, focus radial venous including from
projects longer pipeline a Coated Sundance been placed path commercialization, hold. our Drug Avess our of have on programs including to Several with
studies continue products human we Sundance relates in it the Coated proud clinical a compelling our As that and we of ongoing to Avess balloons, in-human Drug to ongoing. to generated of have first date, is data follow-up for first our be these
see to Endovascular at the conference XX Symposium Sundance holds treating clearly of XX% the real data pleased data, on or was co-lead maintained month patency on population. investigator at These months for professor Ramon Therapy patient use analysis our January on XX show the More trial, month presented disease. we trial for concluded XX that data Sundance the swing XX primary Vascular XX. for and significant the patients ISET recently, Peripheral were associated a from protocol International world our of Sundance, with promise for that Varcoe, artery Based
Given regular and Avess commercial we that we'll to for same SurVeil application the product drug technology drug-coated and that SurVeil, Sundance gain develop the the use similar from -- process DCB balloons. experience PMA use these to of the strategies delivery
of no a in plan Surmodics. very way incredible employee talents spending it implementing decision of including We back, ease the Surmodics adjustment and to taken those a hard of the levels time every impacted, us, our of their stepping reflection value reduction work is and and for our during and in and careful at related the members difficult placement was have our services. the measures severance So team burden staffing
necessary that growth a to of we term with appropriate steps opportunities. of benefit the success both our company spending align of longer is decision term our organization refocused this the and is all near These and for Ultimately, of believe stakeholders. our strategic priorities better its and
look ahead, three focused As strategic remain we priorities. our on we
engage for with our continue evaluate balloon, the FDA with forward. will we the appropriate to the to regulatory progress path as and we prepare respect First, drug-coated SurVeil make strategy to
we of we commercialization and will the Sublime drive revenue and turning radio Device third, our Second, offerings will entry arterial platforms, for market flow to advance and to eventually businesses. initial continue growth. performance from coatings Pounce cash our corner IVD rapid growth Medical And
term represents in best sheet recently value. balance to faced pursuing to have approximately weeks, part access and we the strong and long challenges shareholder believe the objectives sustainable With we growth a these achieving and strategic million for that Despite recent disciplined three creating strong $XX spending approach to initiatives, and and we and remain incremental stable financing, believe debt innovative well are executing core allocation, we of efficient. positioned portfolio businesses, the our committed a capital future technologies, in a enhanced
turn fiscal provide fiscal over now first I'll ’XX and the to Arens, our updated details Tim our Chief guidance. Financial our ’XX call quarter more to Tim? Officer, on
